Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Q24244041)

Europe PubMed Central

title

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (English)

0 references

0 references

0 references

Floris A Van de Laar

1

0 references

Peter LBJ Lucassen

2

0 references

Reinier P Akkermans

3

0 references

Eloy H Van de Lisdonk

4

0 references

Wim JC De Grauw

Cochrane Database of Systematic Reviews

5

0 references

publication date

18 October 2006

0 references

published in

0 references

cites work

Acarbose for patients with hypertension and impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for patients with hypertension and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for type 2 diabetes prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for type 2 diabetes prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

[Acarbose for prevention of diabetes mellitus. STOP-NIDDM]].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Cardiovascular disease risk profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

A systematic review of drug therapy to delay or prevent type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

Acarbose for patients with hypertension and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005061.PUB2